LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

November 6
Last Trade: 3.24 -1.94 -37.45

TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into full development  Multiple TNG462 combination studies planned in 1H 2025  Clinical...Read more


NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of...

November 5
Last Trade: 1.31 -0.005 -0.38

Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND) application filing expected by year-end Additional biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Nov....Read more


Cumberland Pharmaceuticals Receives FDA Orphan Drug and Rare Pediatric Disease Designations for New Treatment of...

November 6
Last Trade: 1.20 0.02 1.27

NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban...Read more


FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing...

November 6
Last Trade: 2.60 -0.08 -2.99

This represents the fourth indication granted a Breakthrough Device Designation for the SCD by FDA DENVER, Nov. 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the...Read more


FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

November 6
Last Trade: 1.05 0.01 0.96

Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the...Read more


Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Medpace 30.03 9.15 $358.27
UnitedHealth 29.66 5.23 $596.69
Humana 27.91 10.71 $288.51
Charles River Laboratories 25.52 13.53 $214.20
McKesson 24.03 4.57 $549.31
ZIVO Bioscience 18.40 1,672.73 $19.50
Chemed 16.82 3.15 $549.99
Masimo 16.07 10.60 $167.63
United Therapeutics 14.72 3.85 $397.49
U.S. Physical Therapy 14.57 17.65 $97.10
Glaukos 12.78 10.00 $140.64
Inspire Medical Systems 12.63 6.35 $211.63
Tempus AI 12.47 28.02 $56.97
Mettler-Toledo 12.40 0.89 $1,398.19
Elevance Health 11.16 2.67 $428.93
Belite Bio 10.98 15.66 $81.08
Finch Therapeutics 10.20 566.67 $12.00
National HealthCare 9.41 7.78 $130.34

Highest Volume

 
CompanyVolumeLast Trade
Pfizer 56,429,480 $27.36
Cardio Diagnostics 50,741,539 $0.36
LifeWallet 39,193,614 $0.12
Vyome 36,361,564 $0.22
CVS Health 26,184,508 $61.61
Sonnet BioTherapeutics 24,847,803 $3.73
Walgreens Boots Alliance 21,158,442 $9.23
Bluejay Diagnostics 19,907,928 $0.09
Teva Pharmaceutical 17,559,156 $17.43
Bionomics 17,050,060 $0.28
Exact Sciences 16,560,836 $54.72
AstraZeneca 15,014,215 $63.85
Tango Therapeutics 14,843,017 $3.24
PacBio 14,468,905 $2.65
Clover Health 14,247,400 $4.35
GSK 13,860,483 $35.90
Oscar Health 12,128,938 $15.55
Shineco 12,127,008 $0.15
Sangamo Therapeutics 11,934,285 $2.47
  • Upcoming FDA Catalysts

    • PTC Therapeutics (NASDAQ: PTCT) PDUFA Date

      November 13, 2024
    • Autolus Therapeutics (NASDAQ: AUTL) PDUFA Date

      November 16, 2024
    • Applied Therapeutics (NASDAQ: APLT) PDUFA Date

      November 28, 2024
    • Applied Therapeutics (NASDAQ: APLT) PDUFA Date

      November 28, 2024
    • BridgeBio Pharma (NASDAQ: BBIO) PDUFA Date

      November 29, 2024
    • Jazz Pharmaceuticals (NASDAQ: JAZZ) PDUFA Date

      November 29, 2024

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Surmodics

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities:

COPYRIGHT ©2023 HEALTH STOCKS HUB